Doing deals in a time of coronavirus

Biotech CEO Bill Haney says 'you focus on the things that make a difference'


Fidelity Management and Research has led a new round for Dragonfly. The new cash brings the total of funds raised from investors and partners to more than $300 million. Then there’s $10 billion more for milestones. Dragonfly has been building their TriNKET technology platform for the innate immune system.

— Merck is expanding their pact with Dragonfly with a $47.5 million payment for upfront and equity to kick up the number of programs they are working on, including new autoimmune drugs.